Clinical Roundup In HER2+ CRC, anti-HER2 therapy may be less toxic alternative to EGFR inhibitors, phase II study finds January 31, 2025Vol.51 No.04
Clinical Roundup Chemo + immunotherapy achieve higher complete remission rates in DLBCL than either treatment alone, Mount Sinai trial finds January 31, 2025Vol.51 No.04
Clinical Roundup Adjuvant Celebrex may reduce risk of colon cancer recurrence in patients with evidence of ctDNA January 31, 2025Vol.51 No.04
Clinical Roundup SWOG study: Statistical tool provides more accurate estimates of recurrence risk and chemotherapy benefit in breast cancer January 24, 2025Vol.51 No.03
Clinical Roundup DFCI researchers use PET imaging to detect body inflammation January 24, 2025Vol.51 No.03
Clinical Roundup Deadly dog cancer reveals clues for improved treatment, UF study finds January 24, 2025Vol.51 No.03
Clinical Roundup NCCN guidelines updated to include ctDNA-MRD testing recommendation for B-cell lymphoma January 17, 2025Vol.51 No.02
Clinical Roundup Trastuzumab emtansine improves OS in HER2+ breast cancer, phase III study shows January 17, 2025Vol.51 No.02
Clinical Roundup Nivolumab demonstrates superiority over standard of care for head-and-neck cancer in phase III trial January 17, 2025Vol.51 No.02
Clinical Roundup Immunotherapy for pediatric osteosarcoma with lung metastases after resection shows positive data January 17, 2025Vol.51 No.02
